Table 1 Clinical characteristics of the BC patients based on TCGA

n

541

542

T stage, n (%)

T1

135 (12.5%)

142 (13.1%)

T2

314 (29.1%)

315 (29.2%)

T3

72 (6.7%)

67 (6.2%)

T4

18 (1.7%)

17 (1.6%)

N stage, n (%)

N0

271 (25.5%)

243 (22.8%)

N1

186 (17.5%)

172 (16.2%)

N2

40 (3.8%)

76 (7.1%)

N3

39 (3.7%)

37 (3.5%)

M stage, n (%)

M0

448 (48.6%)

454 (49.2%)

M1

6 (0.7%)

14 (1.5%)

Pathologic stage, n (%)

Stage I

90 (8.5%)

91 (8.6%)

Stage II

325 (30.7%)

294 (27.7%)

Stage III

109 (10.3%)

133 (12.5%)

Stage IV

5 (0.5%)

13 (1.2%)

Race, n (%)

Asian

22 (2.2%)

38 (3.8%)

Black or African American

100 (10.1%)

81 (8.1%)

White

387 (38.9%)

366 (36.8%)

Age, n (%)

 <  = 60

314 (29%)

287 (26.5%)

 > 60

227 (21%)

255 (23.5%)

Histological type, n (%)

Infiltrating ductal carcinoma

359 (36.7%)

413 (42.3%)

Infiltrating lobular carcinoma

122 (12.5%)

83 (8.5%)

PR status, n (%)

Negative

205 (19.8%)

137 (13.2%)

Indeterminate

3 (0.3%)

1 (0.1%)

Positive

309 (29.9%)

379 (36.7%)

ER status, n (%)

Negative

162 (15.7%)

78 (7.5%)

Indeterminate

0 (0%)

2 (0.2%)

Positive

356 (34.4%)

437 (42.2%)

HER2 status, n (%)

Negative

283 (38.9%)

275 (37.8%)

Indeterminate

3 (0.4%)

9 (1.2%)

Positive

71 (9.8%)

86 (11.8%)

PAM50, n (%)

Normal

34 (3.1%)

6 (0.6%)

LumA

294 (27.1%)

268 (24.7%)

LumB

40 (3.7%)

164 (15.1%)

Her2

46 (4.2%)

36 (3.3%)

Basal

127 (11.7%)

68 (6.3%)

Menopause status, n (%)

Pre

122 (12.6%)

107 (11%)

Peri

23 (2.4%)

17 (1.7%)

Post

331 (34.1%)

372 (38.3%)

Anatomic neoplasm subdivisions, n (%)

Left

272 (25.1%)

291 (26.9%)

Right

269 (24.8%)

251 (23.2%)

radiation_therapy, n (%)

No

219 (22.2%)

215 (21.8%)

Yes

280 (28.4%)

273 (27.7%)

Age, median (IQR)

56 (48, 66)

59 (49, 68)